Altinkaya et al. [212] were the first to show a particularly significant difference between serum apelin levels in patients with endometrial cancer compared to healthy women (215.1 ± 59.8 pg/mL vs. 177.3 ± 55.2 pg/mL). Here, APLN is linked to endometrial cancer.